GLOBAL IN-VITRO FERTILIZATION MARKET FORECAST 2017-2026
KEY FINDINGS
Global In-vitro fertilization market is expected to showcase a healthy CAGR growth of 10.50% over the forecast period of 2017 – 2026. The market growth is chiefly driven by growing infertility rates across the globe. Factors like improved surrogacy laws and high success rate of IVF treatments are further boosting the market expansion.
MARKET INSIGHTS
Products, procedures, and end-users are the primary market segments of the global IVF market. The product segment of this market comprises of equipments and reagents. The various IVF procedures considered for the market includes frozen embryo transfer/replacement, pre-implantation genetic diagnosis, and intra-cytoplasmic sperm injection. The end-users for the market are hospitals and research laboratories, cryobanks and fertility and surgical centers.
REGIONAL INSIGHTS
The regional segmentation of the global IVF market is done into North America, Asia, Europe and rest of the world. Europe and Asia-Pacific are the two regions of the global in-vitro fertilization market that have gained significant importance in recent years. The former market dominated the global scene in 2016 while the latter is predicted to evolve with the fastest CAGR over the forecast period. The European market is mainly propelled by proper government support and rising healthcare expenditure for the IVF market. In the present scenario, the region is also witnessing a sharp rise in the infertility rates, which, in turn, is augmenting the market growth.
COMPETITIVE INSIGHTS
Global companies involved in the in-vitro fertilization market are Auxogyn, Cook Medical Inc, Andrology Solutions, Copper Surgical Inc, Ferring Pharmaceuticals, Esco Micro Pte. Ltd, Genea, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Halotech DNA, Ivftech Aps, Ovascience, Merck Serono, The Baker Company Inc, Vitrolife Ab and Thermo Fisher Scientific Inc.
Global In-vitro fertilization market is expected to showcase a healthy CAGR growth of 10.50% over the forecast period of 2017 – 2026. The market growth is chiefly driven by growing infertility rates across the globe. Factors like improved surrogacy laws and high success rate of IVF treatments are further boosting the market expansion.
MARKET INSIGHTS
Products, procedures, and end-users are the primary market segments of the global IVF market. The product segment of this market comprises of equipments and reagents. The various IVF procedures considered for the market includes frozen embryo transfer/replacement, pre-implantation genetic diagnosis, and intra-cytoplasmic sperm injection. The end-users for the market are hospitals and research laboratories, cryobanks and fertility and surgical centers.
REGIONAL INSIGHTS
The regional segmentation of the global IVF market is done into North America, Asia, Europe and rest of the world. Europe and Asia-Pacific are the two regions of the global in-vitro fertilization market that have gained significant importance in recent years. The former market dominated the global scene in 2016 while the latter is predicted to evolve with the fastest CAGR over the forecast period. The European market is mainly propelled by proper government support and rising healthcare expenditure for the IVF market. In the present scenario, the region is also witnessing a sharp rise in the infertility rates, which, in turn, is augmenting the market growth.
COMPETITIVE INSIGHTS
Global companies involved in the in-vitro fertilization market are Auxogyn, Cook Medical Inc, Andrology Solutions, Copper Surgical Inc, Ferring Pharmaceuticals, Esco Micro Pte. Ltd, Genea, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Halotech DNA, Ivftech Aps, Ovascience, Merck Serono, The Baker Company Inc, Vitrolife Ab and Thermo Fisher Scientific Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE DOMINATES THE GLOBAL IVF MARKET
3.2.2. ASIA PACIFIC AND MIDDLE-EAST MARKET HOLDS GREAT PROMISE FOR THE FORECAST PERIOD
3.2.3. INSURANCE COVERAGE FOR IVF
3.2.4. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. REGIONAL OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. US
8.1.2. CANADA
8.2. EUROPE
8.2.1. UNITED KINGDOM
8.2.2. FRANCE
8.2.3. GERMANY
8.2.4. SPAIN
8.2.5. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. CHINA
8.3.2. INDIA
8.3.3. JAPAN
8.3.4. AUSTRALIA
8.3.5. REST OF ASIA-PACIFIC
8.4. ROW
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE DOMINATES THE GLOBAL IVF MARKET
3.2.2. ASIA PACIFIC AND MIDDLE-EAST MARKET HOLDS GREAT PROMISE FOR THE FORECAST PERIOD
3.2.3. INSURANCE COVERAGE FOR IVF
3.2.4. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. REGIONAL OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. US
8.1.2. CANADA
8.2. EUROPE
8.2.1. UNITED KINGDOM
8.2.2. FRANCE
8.2.3. GERMANY
8.2.4. SPAIN
8.2.5. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. CHINA
8.3.2. INDIA
8.3.3. JAPAN
8.3.4. AUSTRALIA
8.3.5. REST OF ASIA-PACIFIC
8.4. ROW
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
LIST OF TABLES
Table 1 GLOBAL IN-VITRO FERTILIZATION MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 2 GLOBAL AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
Table 3 GLOBAL IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 4 GLOBAL IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 5 GLOBAL REAGENTS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 6 GLOBAL EQUIPMENTS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 7 GLOBAL IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 8 GLOBAL INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 9 GLOBAL PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 10 GLOBAL FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 11 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 12 GLOBAL IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 13 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 14 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY GEOGRAPHY 2017-2026($ MILLION)
Table 15 GLOBAL CRYOBANKS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 16 GLOBAL IVF MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 17 NORTH AMERICA IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 18 EUROPE IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 19 ASIA PACIFIC IVF MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 20 REST OF WORLD IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 1 GLOBAL IN-VITRO FERTILIZATION MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 2 GLOBAL AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
Table 3 GLOBAL IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 4 GLOBAL IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 5 GLOBAL REAGENTS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 6 GLOBAL EQUIPMENTS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 7 GLOBAL IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 8 GLOBAL INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 9 GLOBAL PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 10 GLOBAL FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 11 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 12 GLOBAL IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 13 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 14 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY GEOGRAPHY 2017-2026($ MILLION)
Table 15 GLOBAL CRYOBANKS MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 16 GLOBAL IVF MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 17 NORTH AMERICA IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 18 EUROPE IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 19 ASIA PACIFIC IVF MARKET BY GEOGRAPHY 2017-2026 ($ MILLION)
Table 20 REST OF WORLD IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
LIST OF FIGURES
Figure 1 GLOBAL IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 3 ASIA PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 4 MIDDLE EAST IVF MARKET 2017-2026 ($ MILLION)
Figure 5 EVOLUTION OF IVF MARKET
Figure 6 FALLING BIRTH RATE IN THE US (1960-2015)
Figure 7 GLOBAL REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 8 GLOBAL EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 9 GLOBAL INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 10 GLOBAL PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 11 GLOBAL FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 12 GLOBAL OTHERS MARKET 2017-2026 ($ MILLION)
Figure 13 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 14 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 15 GLOBAL CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 16 INVESTMENT PROPOSITION FOR GLOBAL IVF MARKET BY GEOGRAPHY – 2016
Figure 17 INVESTMENT PROPOSITION FOR GLOBAL IVF MARKET BY END-USER - 2016
Figure 18 CONTRACEPTIVE PREVALENCE AND UNMET NEED FOR FAMILY PLANNING AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS IN NORTH AMERICA IN (%) 2015
Figure 19 NUMBER OF IVF CYCLES PERFORMED IN THE US
Figure 20 UNITED STATES IVF MARKET 2017-2026 ($ MILLION)
Figure 21 FERTILITY RATE IN CANADA (NO. OF CHILD PER WOMEN)
Figure 22 CANADA IVF MARKET 2017-2026 ($ MILLION)
Figure 23 UNITED KINGDOM IVF MARKET 2017-2026 ($ MILLION)
Figure 24 FRANCE IVF MARKET 2017-2026 ($ MILLION)
Figure 25 GERMANY IVF MARKET 2017-2026($MILLION)
Figure 26 SPAIN IVF MARKET 2017-2026 ($ MILLION)
Figure 27 REST OF EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 28 CHINA IVF MARKET 2017-2026 ($ MILLION)
Figure 29 INDIA IVF MARKET 2017-2026 ($ MILLION)
Figure 30 JAPAN IVF MARKET 2017-2026 ($ MILLION)
Figure 31 AUSTRALIA IVF MARKET 2017-2026 ($ MILLION)
Figure 32 REST OF ASIA-PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 33 FERTILITY RATE IN BRAZIL (CHILD PER WOMEN)
Figure 34 LATIN AMERICA IVF MARKET 2017-2026 ($ MILLION)
Figure 35 FERTILITY RATE BY COUNTRIES (CHILD PER WOMEN) 2015
Figure 36 MIDDLE EAST & AFRICA IVF MARKET 2017-2026 ($ MILLION)
Figure 37 GLOBAL IVF MARKET SHARE OF MAJOR COMPANIES – 2016
Figure 1 GLOBAL IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 3 ASIA PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 4 MIDDLE EAST IVF MARKET 2017-2026 ($ MILLION)
Figure 5 EVOLUTION OF IVF MARKET
Figure 6 FALLING BIRTH RATE IN THE US (1960-2015)
Figure 7 GLOBAL REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 8 GLOBAL EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 9 GLOBAL INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 10 GLOBAL PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 11 GLOBAL FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 12 GLOBAL OTHERS MARKET 2017-2026 ($ MILLION)
Figure 13 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 14 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 15 GLOBAL CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 16 INVESTMENT PROPOSITION FOR GLOBAL IVF MARKET BY GEOGRAPHY – 2016
Figure 17 INVESTMENT PROPOSITION FOR GLOBAL IVF MARKET BY END-USER - 2016
Figure 18 CONTRACEPTIVE PREVALENCE AND UNMET NEED FOR FAMILY PLANNING AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS IN NORTH AMERICA IN (%) 2015
Figure 19 NUMBER OF IVF CYCLES PERFORMED IN THE US
Figure 20 UNITED STATES IVF MARKET 2017-2026 ($ MILLION)
Figure 21 FERTILITY RATE IN CANADA (NO. OF CHILD PER WOMEN)
Figure 22 CANADA IVF MARKET 2017-2026 ($ MILLION)
Figure 23 UNITED KINGDOM IVF MARKET 2017-2026 ($ MILLION)
Figure 24 FRANCE IVF MARKET 2017-2026 ($ MILLION)
Figure 25 GERMANY IVF MARKET 2017-2026($MILLION)
Figure 26 SPAIN IVF MARKET 2017-2026 ($ MILLION)
Figure 27 REST OF EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 28 CHINA IVF MARKET 2017-2026 ($ MILLION)
Figure 29 INDIA IVF MARKET 2017-2026 ($ MILLION)
Figure 30 JAPAN IVF MARKET 2017-2026 ($ MILLION)
Figure 31 AUSTRALIA IVF MARKET 2017-2026 ($ MILLION)
Figure 32 REST OF ASIA-PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 33 FERTILITY RATE IN BRAZIL (CHILD PER WOMEN)
Figure 34 LATIN AMERICA IVF MARKET 2017-2026 ($ MILLION)
Figure 35 FERTILITY RATE BY COUNTRIES (CHILD PER WOMEN) 2015
Figure 36 MIDDLE EAST & AFRICA IVF MARKET 2017-2026 ($ MILLION)
Figure 37 GLOBAL IVF MARKET SHARE OF MAJOR COMPANIES – 2016
